Erratum: Sitagliptin attenuates the progression of carotid intima-media thickening in insulin-treated patients with type 2 diabetes: The sitagliptin preventive study of intima-media thickness evaluation (SPIKE). A randomized controlled trial (Diabetes Care (2016) 39 (455-464) DOI: 10.2337/dc15-2145);Sitagliptin attenuates the progression of carotid intima-media thickening in insulin-treated patients with type 2 diabetes: The sitagliptin preventive study of intima-media thickness evaluation (SPIKE): A randomized controlled trial

Diabetes Care

Volumn 39, Issue 3, 2016, Pages 455-464

  Mita, Tomoya ^a   Katakami, Naoto ^b   Shiraiwa, Toshihiko ^c   Yoshii, Hidenori ^d   Onuma, Tomio ^d   Kuribayashi, Nobuichi ^e   Osonoi, Takeshi ^f   Kaneto, Hideaki ^b   Kosugi, Keisuke ^g   Umayahara, Yutaka ^h   Yamamoto, Tsunehiko ⁱ   Matsumoto, Kazunari ^j   Yokoyama, Hiroki ^k   Tsugawa, Mamiko ^l   Gosho, Masahiko ^m   Shimomura, Iichiro ^b   Watada, Hirotaka ^a  

^a JUNTENDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c Shiraiwa Medical Clinic   (Japan)

^d JUNTENDO TOKYO KOTO GERIATRIC MEDICAL CENTER   (Japan)

^e Misaki Naika Clinic   (Japan)

^f Naka Memorial Clinic   (Japan)

^g OSAKA POLICE HOSPITAL   (Japan)

^h OSAKA GENERAL MEDICAL CENTER   (Japan)

ⁱ KANSAI ROSAI HOSPITAL   (Japan)

^j SASEBO CHUO HOSPITAL   (Japan)

^k Jiyugaoka Medical Clinic   (Japan)

^l IKEDA MUNICIPAL HOSPITAL   (Japan)

^m UNIVERSITY OF TSUKUBA   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; SITAGLIPTIN; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR;

ADULT; ANTIDIABETIC ACTIVITY; ARTERIAL WALL THICKNESS; ARTICLE; BODY WEIGHT; COMMON CAROTID ARTERY; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFECT; ECHOGRAPHY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; AGED; ATHEROSCLEROSIS; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; DIAGNOSTIC IMAGING; DISEASE COURSE; DRUG EFFECTS; INTIMA; MIDDLE AGED; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; TUNICA MEDIA;

AGED; ATHEROSCLEROSIS; CAROTID ARTERY, COMMON; CAROTID INTIMA-MEDIA THICKNESS; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DISEASE PROGRESSION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SITAGLIPTIN PHOSPHATE; TUNICA INTIMA; TUNICA MEDIA;

EID: 84962090232     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc17-er06a     Document Type: Erratum

References (38)

1. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339: 229-234
2. Gerstein HC, Miller ME, Byington RP, et al.; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559
3. Patel A, MacMahon S, Chalmers J, et al.; ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-2572
4. Duckworth W, Abraira C, Moritz T, et al.; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-139
5. Frier BM, Schernthaner G, Heller SR. Hypo-glycemia and cardiovascularrisks.Diabetes Care 2011;34(Suppl. 2):S132-S137
6. Strowig SM, Avilés-Santa ML, Raskin P. Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and troglitazone in type 2 diabetes. Diabetes Care 2002;25:1691-1698
7. Nemoto M, TajimaN, Kawamori R. Efficacy of combined use of miglitol in type 2 diabetes patients receiving insulin therapy-placebo-controlled double-blind comparative study. Acta Diabetol 2011;48:15-20
8. Katsuno T, Ikeda H, Ida K, Miyagawa J, Namba M. Add-on therapy with the DPP-4 inhibitor sitagliptin improves glycemic control in insulin-treated Japanese patients with type 2 diabetes mellitus. Endocr J 2013;60: 733-742
9. Shimoda S, Iwashita S, Ichimori S, et al. Efficacy and safety of sitagliptin as add-on therapy on glycemic control and blood glucose fluctuation in Japanese type 2 diabetes subjects ongoing with multiple daily insulin injections therapy. Endocr J 2013;60:1207-1214
10. Sato S, Saisho Y, Kou K, et al. Efficacy and safety of sitagliptin added to insulin in Japanese patients with type 2 diabetes: the EDIT randomized trial. PLoS One 2015;10: e0121988
11. Fonseca V, Schweizer A, Albrecht D, Baron MA, Chang I, Dejager S. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 2007;50:1148-1155
12. Rosenstock J, Rendell MS, Gross JL, Fleck PR, Wilson CA, Mekki Q. Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia. Diabetes Obes Metab 2009;11:1145-1152
13. Matsubara J, Sugiyama S, Sugamura K, et al. A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. J Am Coll Cardiol 2012;59:265-276
14. Ervinna N, Mita T, Yasunari E, et al. Anagliptin, a DPP-4 inhibitor, suppresses proliferation of vascular smooth muscles and mono-cyte inflammatory reaction and attenuates atherosclerosis in male apo E-deficient mice. Endocrinology 2013;154:1260-1270
15. Shah Z, Kampfrath T, Deiuliis JA, et al. Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis. Circulation 2011;124:2338-2349
16. Mita T, Katakami N, Shiraiwa T, et al. Rationale, design, and baseline characteristics of a clinical trial for prevention of atherosclerosis in patients with insulin-treated type 2 diabetes mellitus using DPP-4 inhibitor: the Sitagliptin Preventive Study of Intima-Media Thickness Evaluation (SPIKE). Diabetol Metab Syndr 2014;6:35
17. Araki E, Inagaki N, Inoguchi T, et al.; The Japan Diabetes Society. Treatment Guide for Diabetes. Tokyo, Japan, Bunkodo Co., Ltd, 2014
18. Yokoyama H, Katakami N, Yamasaki Y. Recent advances of intervention to inhibit progression of carotid intima-media thickness in patients with type 2 diabetes mellitus. Stroke 2006;37:2420-2427
19. Plasencia Martínez JM, Garcia Santos JM, Paredes Martinez ML, Pastor AM. Carotid intima-media thickness and hemodynamic parameters: reproducibility of manual measurements with Doppler ultrasound. Med Ultrason 2015; 17:167-174
20. Hodis HN, Mack WJ, Zheng L, et al. Effect of peroxisome proliferator-activated receptor gamma agonist treatment on subclinical atherosclerosis in patients with insulin-requiring type 2 diabetes. Diabetes Care 2006;29:1545-1553
21. Yasunari E, Takeno K, Funayama H, et al. Efficacy of pioglitazone on glycemic control and carotid intima-media thickness in type 2 diabetes patients with inadequate insulin therapy. J Diabetes Investig 2011;2: 56-62
22. Langenfeld MR, Forst T, Hohberg C, et al. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study. Circulation 2005;111:2525-2531
23. Koshiyama H, Shimono D, Kuwamura N, Minamikawa J, Nakamura Y. Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 2001;86:3452-3456
24. Vilsbøll T, Rosenstock J, Yki-Järvinen H, et al. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2010; 12:167-177
25. Mita T, Watada H, Shimizu T, et al. Nategli-nide reduces carotid intima-media thickening in type 2 diabetic patients under good glycemic control. Arterioscler Thromb Vasc Biol 2007; 27:2456-2462
26. Oyama T, Saiki A, Endoh K, et al. Effect of acarbose, an alpha-glucosidase inhibitor, on serum lipoprotein lipase mass levels and common carotid artery intima-media thickness in type 2 diabetes mellitus treated by sulfonylurea. J Atheroscler Thromb 2008;15:154-159
27. Tremblay AJ, Lamarche B, Deacon CF, Weisnagel SJ, Couture P. Effects of sitagliptin therapy on markers of low-grade inflammation and cell adhesion molecules in patients with type 2 diabetes. Metabolism 2014;63:1141-1148
28. Satoh-Asahara N, Sasaki Y, Wada H, et al. A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients. Metabolism 2013;62:347-351
29. Hunt KJ, Baker NL, Cleary PA, Klein R, Virella G, Lopes-Virella MF; DCCT/EDIC Group of Investigators. Longitudinal association between en-dothelial dysfunction, inflammation, and clotting biomarkers with subclinical atherosclerosis in type 1 diabetes: an evaluation of the DCCT/EDIC cohort. Diabetes Care 2015;38: 1281-1289
30. Balestrieri ML, Rizzo MR, Barbieri M, et al. Sirtuin 6 expression and inflammatory activity in diabetic atherosclerotic plaques: effects of in-cretin treatment. Diabetes 2015;64:1395-1406
31. Arakawa M, Mita T, Azuma K, et al. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes 2010;59:1030-1037
32. Nagashima M, Watanabe T, Terasaki M, et al. Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice. Diabetologia 2011;54:2649-2659
33. White WB, Cannon CP, Heller SR, et al.; EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013;369: 1327-1335
34. Scirica BM, Bhatt DL, Braunwald E, et al.; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317-1326
35. Green JB, Bethel MA, Armstrong PW, et al.; TECOS Study Group. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015;373:232-242
36. Holman RR, Sourij H, Califf RM. Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. Lancet 2014; 383:2008-2017
37. Okayama KI, Mita T, Gosho M, et al. Carotid intima-media thickness progression predicts cardiovascular events in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 2013;101:286-292
38. Lorenz MW, Price JF, Robertson C, et al. Carotid intima-media thickness progression and risk of vascular events in people with diabetes: results from the PROG-IMT collaboration. Diabetes Care 2015;38:1921-1929